KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Depreciation & Amortization (CF) (2016 - 2025)

Historic Depreciation & Amortization (CF) for Nektar Therapeutics (NKTR) over the last 16 years, with Q3 2025 value amounting to $196000.0.

  • Nektar Therapeutics' Depreciation & Amortization (CF) fell 8026.18% to $196000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 million, marking a year-over-year decrease of 7954.82%. This contributed to the annual value of $4.4 million for FY2024, which is 4381.32% down from last year.
  • According to the latest figures from Q3 2025, Nektar Therapeutics' Depreciation & Amortization (CF) is $196000.0, which was down 8026.18% from $214000.0 recorded in Q2 2025.
  • In the past 5 years, Nektar Therapeutics' Depreciation & Amortization (CF) ranged from a high of $3.7 million in Q1 2022 and a low of $196000.0 during Q3 2025
  • Its 5-year average for Depreciation & Amortization (CF) is $2.1 million, with a median of $2.2 million in 2023.
  • Its Depreciation & Amortization (CF) has fluctuated over the past 5 years, first surged by 1155.62% in 2021, then crashed by 8533.24% in 2025.
  • Nektar Therapeutics' Depreciation & Amortization (CF) (Quarter) stood at $3.4 million in 2021, then fell by 7.39% to $3.2 million in 2022, then tumbled by 48.08% to $1.7 million in 2023, then crashed by 79.9% to $332000.0 in 2024, then tumbled by 40.96% to $196000.0 in 2025.
  • Its Depreciation & Amortization (CF) stands at $196000.0 for Q3 2025, versus $214000.0 for Q2 2025 and $426000.0 for Q1 2025.